SG11201908088RA - Antibodies against pd-l1 - Google Patents
Antibodies against pd-l1Info
- Publication number
- SG11201908088RA SG11201908088RA SG11201908088RA SG11201908088RA SG 11201908088R A SG11201908088R A SG 11201908088RA SG 11201908088R A SG11201908088R A SG 11201908088RA SG 11201908088R A SG11201908088R A SG 11201908088RA
- Authority
- SG
- Singapore
- Prior art keywords
- genmab
- utrecht
- international
- antibodies
- uppsalalaan
- Prior art date
Links
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000048776 human CD274 Human genes 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT onion °noI0 OilIIIII010010 1111111 Oil ow (10) International Publication Number WO 2018/162749 Al (51) International Patent Classification: C07K 16/10 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/055977 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA 2017 00164 09 March 2017 (09.03.2017) DK PA 2017 00408 11 July 2017 (11.07.2017) DK (71) Applicant: GENMAB A/S [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). (72) Inventors: ALTINTAS, Isil; c/o Genmab B.V., Upp- salalaan 15, 3584 CT Utrecht (NL). SATIJN, David; c/ o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). VAN DEN BRINK, Edward; c/o Genmab B.V., Upp- salalaan 15, 3584 CT Utrecht (NL). VERZIJL, Dennis; c/ o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). RADEMAKER, Rik; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). PARREN, Paul; Werdorperwaard 17, 3984 PR Odijk (NL). DE GOEIJ, Bart; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 16 27 49 Al (74) Agent: GENMAB A/S; Kalvebod Brygge 43, 1560 Copen- hagen V (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: ANTIBODIES AGAINST PD-L1 (57) : The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700164 | 2017-03-09 | ||
DKPA201700408 | 2017-07-11 | ||
PCT/EP2018/055977 WO2018162749A1 (en) | 2017-03-09 | 2018-03-09 | Antibodies against pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908088RA true SG11201908088RA (en) | 2019-10-30 |
Family
ID=61691950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908088R SG11201908088RA (en) | 2017-03-09 | 2018-03-09 | Antibodies against pd-l1 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200239579A1 (en) |
EP (1) | EP3592769B1 (en) |
JP (2) | JP7293121B2 (en) |
KR (1) | KR20190128667A (en) |
CN (2) | CN110573524B (en) |
AU (1) | AU2018231618A1 (en) |
BR (1) | BR112019018533A2 (en) |
CA (1) | CA3055127A1 (en) |
IL (1) | IL269002A (en) |
MA (1) | MA49823A (en) |
MX (1) | MX2019010583A (en) |
SG (1) | SG11201908088RA (en) |
WO (1) | WO2018162749A1 (en) |
ZA (1) | ZA201905822B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3099704B1 (en) | 2014-01-27 | 2021-03-17 | Molecular Templates, Inc. | Mhc class i epitope delivering polypeptides |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
MX2017010072A (en) * | 2015-02-05 | 2017-11-09 | Molecular Templates Inc | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof. |
KR20240038121A (en) | 2015-05-30 | 2024-03-22 | 몰레큘러 템플레이츠, 인코퍼레이션. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
KR102557126B1 (en) | 2016-12-07 | 2023-07-18 | 몰레큘러 템플레이츠, 인코퍼레이션. | Shiga Toxin A Subunit Effector Polypeptides, Shiga Toxin Effector Scaffolds, and Cell-Targeting Molecules for Site-Specific Conjugation |
IL267990B2 (en) | 2017-01-25 | 2024-04-01 | Molecular Templates Inc | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8 t-cell epitopes |
WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
AU2019256383A1 (en) | 2018-04-17 | 2020-11-26 | Celldex Therapeutics, Inc. | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs |
MX2019009726A (en) | 2018-04-17 | 2020-02-05 | Molecular Templates Inc | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds. |
CN109053891B (en) * | 2018-09-17 | 2021-12-21 | 苏州泓迅生物科技股份有限公司 | anti-PD-L1 antibody, and preparation method and application thereof |
WO2020081493A1 (en) * | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
CN113454111A (en) * | 2018-11-06 | 2021-09-28 | 健玛保 | Antibody formulations |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
CN114423793A (en) | 2019-09-18 | 2022-04-29 | 分子模板公司 | PD-L1 binding molecules comprising Shiga toxin A subunit scaffolds |
WO2023057571A1 (en) * | 2021-10-08 | 2023-04-13 | Genmab A/S | Antibodies binding to cd30 and cd3 |
WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
KR970029803A (en) | 1995-11-03 | 1997-06-26 | 김광호 | Precharge Circuit of Semiconductor Memory Device |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
ES2442615T5 (en) | 2002-07-18 | 2023-03-16 | Merus Nv | Recombinant production of antibody mixtures |
WO2005004809A2 (en) | 2003-07-01 | 2005-01-20 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
CN104356236B (en) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
WO2007109254A2 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
JP5718637B2 (en) | 2007-06-21 | 2015-05-13 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and its use |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
CN106432503B (en) | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
KR20110134494A (en) | 2009-03-27 | 2011-12-14 | 자이모제네틱스, 인코포레이티드 | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
JP2012525149A (en) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Method for making heteromultimeric molecules |
KR101224468B1 (en) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | Bispecific antibody having a novel form and use thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
KR101573109B1 (en) * | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
PT2506871T (en) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Antibody fc mutants with ablated effector functions |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
AR080794A1 (en) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
SG184427A1 (en) | 2010-04-20 | 2012-11-29 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
RU2608640C2 (en) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Methods for generation of multispecific and multivalent antibodies |
CN103068846B9 (en) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | Bispecific antibodies comprising disulfide-stabilized Fv fragments |
WO2012025525A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
CN102250246A (en) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | Bispecific antibody to VEGF/PDGFR beta and application thereof |
LT2771364T (en) | 2011-10-27 | 2019-09-10 | Genmab A/S | Production of heterodimeric proteins |
LT2785375T (en) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
NZ630551A (en) | 2012-04-20 | 2017-11-24 | Merus Nv | Methods and means for the production of ig-like molecules |
EP3489254B9 (en) | 2012-04-30 | 2022-12-21 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
ES2848052T3 (en) | 2012-08-03 | 2021-08-05 | Dana Farber Cancer Inst Inc | Single Agent Anti-PD-L1 and PD-L2 Dual Binding Antibodies and Methods of Use |
WO2014055897A2 (en) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
AU2013348570B2 (en) | 2012-11-21 | 2017-01-12 | Pharmabcine Inc. | Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same |
KR20230073341A (en) * | 2013-07-05 | 2023-05-25 | 젠맵 에이/에스 | Humanized or chimeric cd3 antibodies |
CN105669862A (en) * | 2014-11-21 | 2016-06-15 | 上海中信国健药业股份有限公司 | Anti-human PD-L1/KIR bispecific antibody, preparation method and application thereof |
IL310467A (en) | 2015-07-15 | 2024-03-01 | Genmab As | Humanized or chimeric cd3 antibodies |
SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
-
2018
- 2018-03-09 US US16/491,464 patent/US20200239579A1/en not_active Abandoned
- 2018-03-09 CN CN201880028897.5A patent/CN110573524B/en active Active
- 2018-03-09 MA MA049823A patent/MA49823A/en unknown
- 2018-03-09 JP JP2019548675A patent/JP7293121B2/en active Active
- 2018-03-09 AU AU2018231618A patent/AU2018231618A1/en active Pending
- 2018-03-09 KR KR1020197028996A patent/KR20190128667A/en not_active Application Discontinuation
- 2018-03-09 CA CA3055127A patent/CA3055127A1/en active Pending
- 2018-03-09 WO PCT/EP2018/055977 patent/WO2018162749A1/en unknown
- 2018-03-09 MX MX2019010583A patent/MX2019010583A/en unknown
- 2018-03-09 SG SG11201908088R patent/SG11201908088RA/en unknown
- 2018-03-09 CN CN202310819813.2A patent/CN116836285A/en active Pending
- 2018-03-09 BR BR112019018533A patent/BR112019018533A2/en unknown
- 2018-03-09 EP EP18712124.9A patent/EP3592769B1/en active Active
-
2019
- 2019-08-29 IL IL26900219A patent/IL269002A/en unknown
- 2019-09-03 ZA ZA2019/05822A patent/ZA201905822B/en unknown
-
2023
- 2023-06-07 JP JP2023093618A patent/JP2023116610A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA49823A (en) | 2021-04-21 |
CA3055127A1 (en) | 2018-09-13 |
BR112019018533A2 (en) | 2020-04-14 |
WO2018162749A1 (en) | 2018-09-13 |
JP2023116610A (en) | 2023-08-22 |
KR20190128667A (en) | 2019-11-18 |
CN110573524B (en) | 2023-07-18 |
US20200239579A1 (en) | 2020-07-30 |
JP2020511133A (en) | 2020-04-16 |
CN116836285A (en) | 2023-10-03 |
MX2019010583A (en) | 2019-11-25 |
CN110573524A (en) | 2019-12-13 |
ZA201905822B (en) | 2024-01-31 |
AU2018231618A1 (en) | 2019-10-03 |
EP3592769B1 (en) | 2024-05-08 |
EP3592769A1 (en) | 2020-01-15 |
IL269002A (en) | 2019-10-31 |
JP7293121B2 (en) | 2023-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908088RA (en) | Antibodies against pd-l1 | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201805870YA (en) | Bispecific t cell engaging antibody constructs | |
SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201909154SA (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201805770UA (en) | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201908772TA (en) | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof |